Barclays
STRO icon

Barclays’s Sutro Biopharma STRO Stock Holding History

Barclays’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
36,954
+36,815
+26,486% +$1.15M ﹤0.01% 2672
2026
Q1 		$3.46K Buy
+139
New +$2.51K ﹤0.01% 4807
2025
Q4 		– Sell
-277
Closed -$2.4K – 5665
2025
Q3 		$2.4K Sell
277
-385
-58% -$3.28K ﹤0.01% 5135
2025
Q2 		$4.72K Sell
662
-10,967
-94% -$89.7K ﹤0.01% 4981
2025
Q1 		$75.7K Sell
11,629
-4,252
-27% -$67K ﹤0.01% 4491
2024
Q4 		$292K Sell
15,881
-11,421
-42% -$349K ﹤0.01% 4131
2024
Q3 		$945K Buy
27,302
+21,676
+385% +$850K ﹤0.01% 3390
2024
Q2 		$165K Sell
5,626
-2,348
-29% -$92.8K ﹤0.01% 3677
2024
Q1 		$451K Sell
7,974
-5,232
-40% -$231K ﹤0.01% 3659
2023
Q4 		$567K Buy
13,206
+6,948
+111% +$220K ﹤0.01% 3803
2023
Q3 		$217K Buy
6,258
+1,809
+41% +$78.8K ﹤0.01% 3255
2023
Q2 		$207K Sell
4,449
-7,665
-63% -$382K ﹤0.01% 3221
2023
Q1 		$560K Buy
12,114
+3,924
+48% +$249K ﹤0.01% 3184
2022
Q4 		$662K Buy
8,190
+6,147
+301% +$427K ﹤0.01% 3117
2022
Q3 		$114K Sell
2,043
-341
-14% -$20.2K ﹤0.01% 3489
2022
Q2 		$125K Sell
2,384
-2,975
-56% -$166K ﹤0.01% 3677
2022
Q1 		$441K Sell
5,359
-30,080
-85% -$2.86M ﹤0.01% 2988
2021
Q4 		$5.27M Buy
35,439
+2,377
+7% +$426K ﹤0.01% 1674
2021
Q3 		$6.25M Buy
33,062
+9,163
+38% +$1.74M ﹤0.01% 1479
2021
Q2 		$4.44M Sell
23,899
-2,113
-8% -$414K ﹤0.01% 1665
2021
Q1 		$5.92M Buy
26,012
+3,000
+13% +$712K ﹤0.01% 1388
2020
Q4 		$5M Sell
23,012
-901
-4% -$149K ﹤0.01% 1528
2020
Q3 		$2.4M Buy
23,913
+177
+0.7% +$16.7K ﹤0.01% 1942
2020
Q2 		$1.84M Buy
23,736
+742
+3% +$71.2K ﹤0.01% 2202
2020
Q1 		$2.35M Buy
22,994
+21,164
+1,157% +$2.22M ﹤0.01% 2152
2019
Q4 		$202K Buy
1,830
+557
+44% +$57.4K ﹤0.01% 5021
2019
Q3 		$116K Buy
1,273
+300
+31% +$30.3K ﹤0.01% 5369
2019
Q2 		$111K Buy
973
+792
+438% +$87.3K ﹤0.01% 5603
2019
Q1 		$21K Buy
181
+81
+81% +$8.43K ﹤0.01% 6347
2018
Q4 		$9K Buy
+100
New +$12.1K ﹤0.01% 6228

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Barclays's STRO Position: Q2 2026 in Review

Barclays increased its Sutro Biopharma (STRO) stake by 26,486% in Q2 2026, buying an estimated $1.15M and bringing the position to 36,954 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2672.

Barclays first reported a position in STRO in Q4 2018 and has held it in 30 quarters since. The position peaked at $6.25M in Q3 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Barclays held 36,954 shares of Sutro Biopharma worth $1.23M as of Q2 2026.
  • Barclays bought 36,815 Sutro Biopharma shares in Q2 2026, an estimated $1.15M.
  • Sutro Biopharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2672 holding.
  • Barclays first reported a position in Sutro Biopharma in Q4 2018 and has held it in 30 quarters since.
  • Barclays's Sutro Biopharma position peaked at $6.25M in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.